专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06355665B1 1H-4(5)-substituted imidazole derivatives, their preparation and their use as histamine H3 receptor ligands 失效
标题翻译： 1H-4（5） - 取代咪唑衍生物，其制备及其作为组胺H3受体配体的用途
公开(公告)号：US06355665B1
公开(公告)日：2002-03-12
申请号：US09463012
申请日：2000-03-14
申请人： Matthew John Tozer , Sarkis Barret Kalindjian , Ian Duncan Linney , Katherine Isabel Mary Steel , Michael John Pether , Tracey Cooke
发明人： Matthew John Tozer , Sarkis Barret Kalindjian , Ian Duncan Linney , Katherine Isabel Mary Steel , Michael John Pether , Tracey Cooke
IPC分类号： C07D23354
CPC分类号： C07D233/64 , C07D417/04
摘要： A compound of the formula wherein R2 is an optionally substituted Cz to Cg alkylene or alkylene chain; R3 is C2 to C15 optionally substituted hydrocarbyl; X is a bond or —NR4—, wherein R4 is hydrogen or non-aromatic C1 to C5 optionally substituted hydrocarbyl, or aryl(C1 to C3)alkyl, or a pharmaceutically acceptable salt thereof. A method of modifing histamine activity in a patient comprising administering to said patient a pharmaceutical composition containing an effective amount of a compound of formula wherein R1 is selected from C1 to C6 alkyl, C1 to C6 alkoxy, C1 to C6 alkylthio, carboxy, carboxy(C1 to C6)alkyl, formyl, C1 to C6 alkylcarbonyl, C1 to C6 alkylcarbonylalkoxy, nitro, trihalomethyl, hydroxy, amino, C1 to C6 alkylcarbonylalkoxy, nitro, trihalomethyl, hydroxy, amino, C1 to C6 alkylamino, di(C1 to C6 alkyl)amino, aryl, C1 to C6 alkylaryl, halo, sulfamoyl and cyano; R2 is optionally substituted C2 to C20 hydrocarbylene, in which one or more hydrogen atoms may be replaced by halogen atoms and up to 6 carbon atoms may be replaced by oxygen or nitrogen atoms, R2 being in the form of an optionally substituted C2 to C8 alkylene or alkenylene chain; R3 is hydrogen or C1 to C15 optionally substituted hydrocarbyl; X is a bond or —NR4—; and a is from 0 to 2, or a pharmaceutically acceptable salt thereof.
摘要翻译：化学式R 2的化合物是任选取代的C 1至C 8亚烷基或亚烷基链; R3是C2至C15任选取代的烃基; X是键或-NR 4 - ，其中R 4是氢或非芳族C 1至C 5任选取代的烃基或芳基（C 1至C 3）烷基或其药学上可接受的盐。1，一种修饰患者组胺活性的方法，向所述患者施用含有有效量的蛔虫素R1化合物的药物组合物选自C1至C6烷基，C1至C6烷氧基，C1至C6烷硫基，羧基，羧基（C1至C6）烷基，甲酰基，C1至C6 烷基羰基，C 1至C 6烷基羰基烷氧基，硝基，三卤代甲基，羟基，氨基，C 1至C 6烷基羰基烷氧基，硝基，三卤甲基，羟基，氨基，C 1至C 6烷基氨基，二（C 1至C 6烷基）氨基，芳基，C 1至C 6烷基芳基，，氨磺酰基和氰基; R2是任选取代的C 2至C 20亚烃基，其中一个或多个氢原子可以被卤素原子取代，并且最多6个碳原子可被氧或氮原子取代，R 2为任选取代的C 2至C 8亚烷基或亚烯基链; R 3是氢或C 1至C 15任选取代的烃基; X是键或-NR4-; 和a为0至2，或其药学上可接受的盐。

2. 发明授权

US06479531B1 Gastrin and cholecystokinin receptor ligands 失效
标题翻译：胃泌素和胆囊收缩素受体配体
公开(公告)号：US06479531B1
公开(公告)日：2002-11-12
申请号：US09831385
申请日：2001-08-02
申请人： Sarkis Barret Kalindjian , Ildiko Maria Buck , Ian Duncan Linney , Paul Trevor Wright , Iain Mair McDonald , Katherine Isobel Mary Steel , Robert Antony David Hull , Sonia Patricia Roberts , John David Gaffen , Jeremy Gilbert Vinter , Martin Keith Walker , James Whyte Black , Gillian Fairfull Watt , Elaine Anne Harper , Nigel Paul Shankley , Matthew John Tozer , David John Dunstone , Michael John Pether , Elliot James Lilley , David Andrew Sykes , Caroline Minli Rachel Low , Eric Peter Griffin , Laurence Wright
发明人： Sarkis Barret Kalindjian , Ildiko Maria Buck , Ian Duncan Linney , Paul Trevor Wright , Iain Mair McDonald , Katherine Isobel Mary Steel , Robert Antony David Hull , Sonia Patricia Roberts , John David Gaffen , Jeremy Gilbert Vinter , Martin Keith Walker , James Whyte Black , Gillian Fairfull Watt , Elaine Anne Harper , Nigel Paul Shankley , Matthew John Tozer , David John Dunstone , Michael John Pether , Elliot James Lilley , David Andrew Sykes , Caroline Minli Rachel Low , Eric Peter Griffin , Laurence Wright
IPC分类号： C07D40306
CPC分类号： C07D233/64 , C07D207/34 , C07D233/88 , C07D233/90 , C07D263/34 , C07D277/56 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/04
摘要： Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—═CH—, —S— or —O—. n is from 1 to 4; R1 is H or C1 to C15 hydrocarbyl R2 is selected from H, Me, Et, Pr and OH, R3 is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or R2 and R3 on the same carbon atom together represent an ═O group; R4 is C1 to C15 hydrocarbyl Z is —(NR7)a—CO—(NR8)b— (wherein a is 0 or 1, b is 0 or 1, —CO—NR7—CH2—CO—NR8—, —CO—O—, —CH2—CH2—, —CH═CH—, —CH2—NR8— or a bond; Q is —R9V, or (II), (wherein R9 is —CH2—; —CH2—CH2—; or (III), R9 and R8, together with the nitrogen atom to which R8 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is —CO—NH—SO2—Ph, —SO2—NH—CO—Ph, —CH2OH, or a group of the formula —R10U, (wherein U is —COOH, tetrazolyl, —CONHOH— or —SO3H; and R10 is a bond; C1 to C6 hydrocarbylene, —O—(C1 to C3 alkylene)—; —SO2NR11—CHR12—; —CO—NR11—CHR12—, or —NH—(CO)c—CH2—, c being 0 or 1).
摘要翻译：式（I）化合物及其药学上可接受的盐是胃泌素和/或胆囊收缩素受体的配体。 X和Y独立地为= N-，-N（R 5） - = CH - ， - S-或-O-。 n为1至4; R1为H或C1至C15烃基R2选自H，Me，Et，Pr和OH，R3选自H，Me，Et和Pr; 或（当n大于1时），每个R 3独立地选自H，Me，Et和Pr，或相邻碳原子上的两个R 3基团连接形成C 3至C 6碳环，或在相同碳上的R 2和R 3 原子一起代表a = O组; R4为C1〜C15烃基Z为 - （NR7）a-CO-（NR8）b-（其中a为0或1，b为0或1，-CO-NR7-CH2-CO-NR8-，-CO- O，-CH 2 -CH 2 - ， - CH = CH - ， - CH 2 -NR 8 - 或键; Q为-R 9 V或（II）（其中R 9为-CH 2 - ; -CH 2 -CH 2 - III），R9和R8与R8所连接的氮原子一起形成被V取代的哌啶或吡咯烷环; V是-CO-NH-SO 2-Ph，-SO 2 -NH-CO-Ph， -CH 2 OH或式-R 10 U的基团（其中U为-COOH，四唑基，-CONHOH-或-SO 3 H; R 10为键; C 1至C 6亚烃基，-O-（C 1至C 3亚烷基） - ; -SO2NR11-CHR12-; -CO-NR11-CHR12-或-NH-（CO）c-CH2-，c为0或1）。

3. 发明授权

US6080871A Sulfonamides and sulfamides as H.sub.3 receptor antagonists 失效
标题翻译：磺酰胺和磺酰胺作为H3受体拮抗剂
公开(公告)号：US6080871A
公开(公告)日：2000-06-27
申请号：US117808
申请日：1998-10-06
申请人： Sarkis Barret Kalindjian , Nigel Paul Shankley , Matthew John Tozer , Iain Mair McDonald , Michael John Pether , Elaine Anne Harper , Gillian Fairfull Watt , Tracey Cooke , Caroline Minli Rachel Low
发明人： Sarkis Barret Kalindjian , Nigel Paul Shankley , Matthew John Tozer , Iain Mair McDonald , Michael John Pether , Elaine Anne Harper , Gillian Fairfull Watt , Tracey Cooke , Caroline Minli Rachel Low
IPC分类号： A61K31/00 , A61K31/415 , A61K31/4164 , A61K31/417 , A61P43/00 , C07D233/54 , C07D233/64 , C07D401/12
CPC分类号： C07D233/64 , C07D401/12
摘要： Compounds of formula (I) or (II) wherein R.sup.1 is C.sub.4 to C.sub.20 hydrocarbyl (in which one or more hydrogen atoms may be replaced by halogen, and up to three carbon atoms may be replaced by oxygen, nitrogen or sulphur atoms, provided that R.sup.1 does not contain an --O--O-- group), R.sup.2 is H or C.sub.1 to C.sub.3 alkyl, m is from 1 to 15, n is from 2 to 6, each X group is independently (a), or one X group is --N(R.sup.4)--, --O-- or --S-- and the remaining X groups are independently (a), wherein R.sup.3 is H, C.sub.1 to C.sub.6 alkyl, --CO.sub.2 R.sup.5, --CONR.sup.5.sub.2, --CR.sup.5.sub.2 OR.sup.6 or --OR.sup.5 (in which R.sup.5 and R.sup.6 are H or C.sub.1 to C.sub.3 alkyl), and R.sup.4 is H or C.sub.1 to C.sub.6 alkyl, each Y group is independently --C(R.sup.3)R.sup.4 --, or up to two Y groups are --N(R.sup.4)--, --O-- or --S-- and the remaining Y groups are independently --C(R.sup.3)R.sup.4 --, wherein R.sup.3 is as defined above, one R.sup.4 group in the structure is imidazoyl or imidazoylalkyl and the remaining R.sup.4 groups are H or C.sub.1 to C.sub.6 alkyl, and Z is >C(R.sup.7)NR.sup.2 -- or >N--, wherein R.sup.7 is any of the groups recited above for R.sup.3, and pharmaceutically acceptable salts thereof are ligands at histamine H.sub.3 receptors. ##STR1##
摘要翻译： PCT No.PCT / GB97 / 00358 Sec。 371 1998年10月6日第 102（e）日期1998年10月6日PCT 1997年2月10日提交PCT公布。第WO97 / 29092号公报日期1997年8月14日其中R 1为C 4至C 20烃基（其中一个或多个氢原子可以被卤素取代，并且最多三个碳原子）可以被氧，氮或氮取代的式（I）或（II）硫原子，条件是R1不含有-OO-基），R2为H或C1至C3烷基，m为1至15，n为2-6，X基团独立地为（a）或一个 X基团是-N（R 4） - ， - O-或-S-，其余的X基团独立地是（a），其中R 3是H，C 1 -C 6烷基，-CO 2 R 5，-CONR 52，-CR 52 OR 6或-OR 5（其中R5和R6是H或C1-C3烷基），R4是H或C1-C6烷基，每个Y基团独立地是-C（R3）R4-，或者最多两个Y基团是-N（R4） - ，-O-或-S-，其余的Y基团独立地为-C（R 3）R 4 - ，其中R 3如上定义，结构中的一个R 4基团为咪唑基或咪唑基烷基，其余的R 4基团为H或C 1至 C6烷基，并且Z是> C（R7）NR2-或> N-，其中R7是上述对R3所述的任何基团，并且药物其可用的盐是组胺H3受体的配体。

4. 发明授权

US5795907A Gastin and CCK receptor ligands 失效
标题翻译：加斯汀和CCK受体配体
公开(公告)号：US5795907A
公开(公告)日：1998-08-18
申请号：US583008
申请日：1996-03-18
申请人： Sarkis Barret Kalindjian , Katherine Isobel Mary Steel , Michael John Pether , Jonathan Michael Richard Davies , Caroline Minli Rachel Low , Martin Lyn Hudson , Ildiko Maria Buck , Iain Mair McDonald , David John Dunstone , Matthew John Tozer
发明人： Sarkis Barret Kalindjian , Katherine Isobel Mary Steel , Michael John Pether , Jonathan Michael Richard Davies , Caroline Minli Rachel Low , Martin Lyn Hudson , Ildiko Maria Buck , Iain Mair McDonald , David John Dunstone , Matthew John Tozer
IPC分类号： C07C233/65 , C07C233/82 , C07C237/22 , C07C237/48 , C07D207/16 , C07D209/08 , C07D209/42 , C07D209/88 , C07D217/26 , C07D235/06 , C07D235/24 , C07D307/84 , C07D333/70 , C07D401/06 , C07D403/06 , C07D403/12 , C07D403/14 , C07D453/02 , C07D471/04 , A61K31/40 , A61K31/415 , C07D415/54
CPC分类号： C07D235/06 , C07C233/65 , C07C233/82 , C07C237/22 , C07C237/48 , C07D207/16 , C07D209/08 , C07D209/42 , C07D209/88 , C07D217/26 , C07D235/24 , C07D307/84 , C07D333/70 , C07D401/06 , C07D403/06 , C07D403/12 , C07D403/14 , C07D453/02 , C07D471/04 , C07C2103/74
摘要： Compounds of formula (Ia), (Ib), or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R.sup.1.sub.(m) represents up to 6 substituents, K represents --O--, --S--, --CH.sub.2 --, --N(R.sup.2)-- or --N(COR.sup.2)--, in which R.sup.2 is H or C.sub.1 to C.sub.3 alkyl, W is a carbonyl, sulfonyl or sulfinyl group, provided that at least one of W and X contains carbonyl, Y and Z are as given in the description, and their pharmaceutically acceptable salts are ligands at CCK and/or gastrin receptors. ##STR1##
摘要翻译： PCT No.PCT / GB94 / 01741 Sec。 371日期：1996年3月18日 102（e）1996年3月18日PCT 1994年8月9日PCT PCT。公开号WO95 / 04720 日期：1995年2月16日，式（Ia），（Ib）或（Ic）的化合物，其中A表示具有两个稠合环的基团或式（Id）的基团，R 1（m） K表示-O - ， - S - ， - CH 2 - ， - N（R 2） - 或-N（COR 2） - ，其中R 2是H或C 1至C 3烷基，W是羰基，磺酰基或亚磺酰基， W和X中的至少一个含有羰基，Y和Z如说明书中给出，并且其药学上可接受的盐是CCK和/或胃泌素受体的配体。（Ia）（Ib）（Ic）（Id）

5. 发明授权

US06878734B2 Gastrin and cholecystokinin receptor ligands(II) 失效
公开(公告)号：US06878734B2
公开(公告)日：2005-04-12
申请号：US10275741
申请日：2001-05-04
申请人： Sarkis Barret Kalindjian , Ildiko Maria Buck , Katherine Isobel Mary Steel , Paul Trevor Wright , Matthew John Tozer , Michael John Pether , Caroline Minli Rachel Low
发明人： Sarkis Barret Kalindjian , Ildiko Maria Buck , Katherine Isobel Mary Steel , Paul Trevor Wright , Matthew John Tozer , Michael John Pether , Caroline Minli Rachel Low
IPC分类号： A61K31/42 , A61K45/06 , A61P1/04 , C07D233/54 , C07D403/04 , C07D413/04 , C07D417/04 , A61K31/415 , C07D233/06 , C07D237/08 , C07D247/02 , C07D405/04 , C07D413/02
CPC分类号： C07D233/64 , A61K31/42 , A61K45/06 , C07D403/04 , C07D413/04 , C07D417/04 , A61K2300/00
摘要： Ligands for the gastrin and cholecystokinin (CCK) receptors are provided, together with methods for preparing such ligands, and compounds which are useful intermediates in such methods. Pharmaceutical compositions comprising such ligands, methods for preparing such pharmaceutical compositions, and methods of treatment using these compositions also are provided. The ligands have the formula (I): where n is from 1 to 3; X and Y are independently ═N— or —N(R5)— where R5 is selected from the group consisting of H, Me, Et, Pr, Bn, —OH and —CH2COOR6, where R6 represents H, Me, Et, Pr or Bn; R1 is H or a C1-C15 saturated carbocylic ring optionally substituted with OMe, NMe2, CF3, Me, F, Cl, Br or I where up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 is selected from the group consisting of H, Me, Et and Pr when n is 1; or, when n is greater than 1, each R3 is independently selected from the group consisting of H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an ═O group; R4 is H or a C3 to C10 alicyclic ring where up to three H atoms may optionally be replaced by halogen atoms; Z is selected from the group consisting of: Q is a 6-membered aromatic carbocycle substituted with 1 or 2 V groups and optionally substituted with 1, 2 or 3 T groups; V is selected from the group consisting of —CO—NH—SO2—Ph, —SO2—NH—CO—Ph, —CH2OH, or a group of the formula —R7U, where U is selected from the group consisting of —COOH, tetrazolyl, —CONHOH and —SO3H; and R7 is selected from the group consisting of a bond; C1 to C6 hydrocarbylene, optionally substituted by hydroxy, amino or acetamido; —O—(C1 to C3 alkylene)-; —SO2NR8—CHR9—; —CO—NR8—CHR9—, where R8 and R9 are independently selected from H and methyl; and —NH—(CO)c—CH2—, where c is 0 or 1.

6. 发明授权

US5919829A Gastrin and cck receptor ligands 失效
标题翻译：胃泌素和cck受体配体
公开(公告)号：US5919829A
公开(公告)日：1999-07-06
申请号：US64849
申请日：1998-04-23
申请人： Sarkis Barret Kalindjian , Katherine Isobel Mary Steel , Michael John Pether , Jonathan Michael Richard Davies , Caroline Minli Rachel Low , Martin Lyn Hudson , Ildiko Maria Buck , Iain Mair McDonald , David John Dunstone , Matthew John Tozer
发明人： Sarkis Barret Kalindjian , Katherine Isobel Mary Steel , Michael John Pether , Jonathan Michael Richard Davies , Caroline Minli Rachel Low , Martin Lyn Hudson , Ildiko Maria Buck , Iain Mair McDonald , David John Dunstone , Matthew John Tozer
IPC分类号： A61K31/38 , A61K31/40 , A61K31/403 , A61K31/404 , A61K31/41 , A61K31/415 , A61K31/4184 , A61K31/47 , A61K31/472 , A61P1/00 , A61P1/16 , A61P3/04 , A61P25/20 , A61P29/00 , A61P35/00 , A61P43/00 , C07C233/65 , C07C233/81 , C07C233/82 , C07C233/83 , C07C237/22 , C07C237/48 , C07D207/09 , C07D207/16 , C07D209/08 , C07D209/42 , C07D209/88 , C07D217/26 , C07D235/04 , C07D235/06 , C07D235/22 , C07D235/24 , C07D307/79 , C07D307/84 , C07D333/70 , C07D401/06 , C07D403/06 , C07D403/12 , C07D403/14 , C07D453/02 , C07D471/04 , C07D415/54
CPC分类号： C07D235/06 , C07C233/65 , C07C233/82 , C07C237/22 , C07C237/48 , C07D207/16 , C07D209/08 , C07D209/42 , C07D209/88 , C07D217/26 , C07D235/24 , C07D307/84 , C07D333/70 , C07D401/06 , C07D403/06 , C07D403/12 , C07D403/14 , C07D453/02 , C07D471/04 , C07C2103/74
摘要： Compounds of formula (Ia), (Ib), or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R.sup.1.sub.(m) represents up to 6 substituents, K represents --O--, --S--, --CH.sub.2 --, --N(R.sup.2)-- or --N(COR.sup.2)--, in which R.sup.2 is H or C.sub.1 to C.sub.3 alkyl, W is a carbonyl, sulfonyl or sulfinyl group, provided that at least one of W and X contains carbonyl, Y and Z are as given in the description, and their pharmaceutically acceptable salts are ligands at CCK and/or gastrin receptors. ##STR1##
摘要翻译：式（Ia），（Ib）或（Ic）的化合物，其中A表示具有两个稠环的基团或式（Id）的基团，R 1（m）表示至多6个取代基，K表示-O- ，-S-，-CH 2 - ， - N（R 2） - 或-N（COR 2） - ，其中R 2是H或C 1至C 3烷基，W是羰基，磺酰基或亚磺酰基，条件是至少一个 W和X含有羰基，Y和Z如说明书中所给出，其药学上可接受的盐是CCK和/或胃泌素受体的配体。

7. 发明授权

US07034048B2 Gastrin and cholecystokinin receptor ligands (III) 失效
公开(公告)号：US07034048B2
公开(公告)日：2006-04-25
申请号：US10275613
申请日：2001-05-04
申请人： Sarkis Barret Kalindjian , Ildiko Maria Buck , Caroline Minli Rachel Low , Matthew John Tozer
发明人： Sarkis Barret Kalindjian , Ildiko Maria Buck , Caroline Minli Rachel Low , Matthew John Tozer
IPC分类号： A61K31/4164 , A61K31/404 , C07D403/04
CPC分类号： C07D403/04 , A61K31/415 , A61K31/42 , A61K45/06 , C07D413/04 , A61K2300/00
摘要： Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently ═N—, —N(R5)—(R5 being selected from H, Me, Et, Pr, Bn, OH and —CH2COOR6, wherein R6 represents H, Me, Et, Pr or Bn), ═CH—, —O— or —S—; n is from 1 to 4; A is an optionally substituted 5- or 6-membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; R1 is H or C1 to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an ═O group; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is —CO—NH—SO2—Ph, —SO2—NH—CO—PH, —CH2OH, or a group of the formula —R7U, (wherein U is —COOH, tetrazolyl, —CONHOH or —SO3H; and R7 is a bond; C1 to C6 hydrocarbylene optionally substituted by hydroxy, amino or acetamido; —O—(C1 to C3 alkylene)—; —SO2NR8—CHR9—; —CO—NR8—CHR9—, R8 and R9 being independently selected from H and methyl; or —NH—(CO)c—CH2, c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described

8. 发明授权

US08435968B2 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use 有权
标题翻译：芳基 - 苯基 - 磺酰氨基 - 环烷基化合物及其用途
公开(公告)号：US08435968B2
公开(公告)日：2013-05-07
申请号：US13063956
申请日：2009-09-18
申请人： Iain Robert Greig , Rose Mary Sheridan , Raymond Fisher , Matthew John Tozer , Juha Andrew Clase , Andrew Smith , Andrew Robert Tuffnell , Robert Jurgen Van 't Hof
发明人： Iain Robert Greig , Rose Mary Sheridan , Raymond Fisher , Matthew John Tozer , Juha Andrew Clase , Andrew Smith , Andrew Robert Tuffnell , Robert Jurgen Van 't Hof
IPC分类号： A61K31/69 , A61K31/18 , A61K31/505 , A61K31/5375 , A61K31/40 , C07D239/30 , C07D213/61 , C07D265/30 , C07D207/04
CPC分类号： A61K31/18 , A61K31/44 , A61K31/4418 , A61K31/505 , C07C311/20 , C07C311/28 , C07C311/29 , C07D207/04 , C07D213/34 , C07D213/52 , C07D213/61 , C07D239/26 , C07D239/30 , C07D295/135
摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).
摘要翻译：本发明一般涉及治疗化合物领域，更具体地涉及下列通式的某些芳基 - 苯基 - 亚磺酰氨基 - 环烷基化合物（在本文中统称为“APSAC化合物”）。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内在治疗例如炎症和/或关节破坏和/或骨丢失中的用途; 由免疫系统的过度和/或不适当和/或延长的激活介导的疾病; 炎性和自身免疫性疾病，例如类风湿性关节炎，牛皮癣，牛皮癣关节炎，慢性阻塞性肺病（COPD），动脉粥样硬化，炎性肠病，强直性脊柱炎等; 与骨丢失相关的疾病，例如与类风湿性关节炎中的过度破骨细胞活性相关的骨丢失，骨质疏松症，癌症相关的骨病，佩吉特氏病等; 和癌症，如血液恶性肿瘤，实体肿瘤等。式（I）。

9. 发明授权

US08207167B2 Aryl-phenyl-sulfonamide-phenylene compounds and their use 有权
标题翻译：芳基 - 苯基 - 磺酰胺 - 亚苯基化合物及其用途
公开(公告)号：US08207167B2
公开(公告)日：2012-06-26
申请号：US13063950
申请日：2009-09-18
申请人： Iain Robert Greig , Rose Mary Sheridan , Raymond Fisher , Matthew John Tozer , Juha Andrew Clase , Andrew Smith , Andrew Robert Tuffnell , Robert Jurgen Van 't Hof
发明人： Iain Robert Greig , Rose Mary Sheridan , Raymond Fisher , Matthew John Tozer , Juha Andrew Clase , Andrew Smith , Andrew Robert Tuffnell , Robert Jurgen Van 't Hof
IPC分类号： A61K31/5375 , A61K31/18 , C07D265/30 , C07C311/01
CPC分类号： C07D303/36 , C07C311/21 , C07C311/39 , C07C2601/02 , C07D239/26 , C07D239/30 , C07D263/20 , C07D295/135
摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumor, etc.
摘要翻译：本发明一般涉及治疗化合物领域，更具体地涉及下列通式（I）的某些芳基 - 苯基 - 亚磺酰氨基 - 亚苯基化合物（本文统称为“APSAP化合物”）。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内在治疗例如炎症和/或关节破坏和/或骨丢失中的用途; 由免疫系统的过度和/或不适当和/或延长的激活介导的疾病; 炎性和自身免疫性疾病，例如类风湿性关节炎，牛皮癣，牛皮癣关节炎，慢性阻塞性肺病（COPD），动脉粥样硬化，炎性肠病，强直性脊柱炎等; 与骨丢失相关的疾病，例如与类风湿性关节炎中的过度破骨细胞活性相关的骨丢失，骨质疏松症，癌症相关的骨病，佩吉特氏病等; 和癌症，如血液恶性肿瘤，实体瘤等。

10. 发明申请

US20130245018A1 Aryl-Phenyl-Sulfonamido-Cycloalkyl Compounds and Their Use 有权
标题翻译：芳基 - 苯基磺酰氨基 - 环烷基化合物及其用途
公开(公告)号：US20130245018A1
公开(公告)日：2013-09-19
申请号：US13886799
申请日：2013-05-03
申请人： Iain Robert Greig , Rose Mary Sheridan , Raymond Fisher , Matthew John Tozer , Juha Andrew Clase , Andrew Smith , Andrew Robert Tuffnell , Robert Jurgen Van 't Hof
发明人： Iain Robert Greig , Rose Mary Sheridan , Raymond Fisher , Matthew John Tozer , Juha Andrew Clase , Andrew Smith , Andrew Robert Tuffnell , Robert Jurgen Van 't Hof
IPC分类号： C07C311/20 , C07D239/26 , C07D213/61 , C07D239/30 , C07D207/04 , C07D295/135
CPC分类号： A61K31/18 , A61K31/44 , A61K31/4418 , A61K31/505 , C07C311/20 , C07C311/28 , C07C311/29 , C07D207/04 , C07D213/34 , C07D213/52 , C07D213/61 , C07D239/26 , C07D239/30 , C07D295/135
摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc.
摘要翻译：本发明一般涉及治疗化合物领域，更具体地涉及下列通式的某些芳基 - 苯基 - 亚磺酰氨基 - 环烷基化合物（在本文中统称为“APSAC化合物”）。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内在治疗例如炎症和/或关节破坏和/或骨丢失中的用途; 由免疫系统的过度和/或不适当和/或延长的激活介导的疾病; 炎性和自身免疫性疾病，例如类风湿性关节炎，牛皮癣，牛皮癣关节炎，慢性阻塞性肺病（COPD），动脉粥样硬化，炎性肠病，强直性脊柱炎等; 与骨丢失相关的疾病，例如与类风湿性关节炎中的过度破骨细胞活性相关的骨丢失，骨质疏松症，癌症相关的骨病，佩吉特氏病等; 和癌症，如血液恶性肿瘤，实体瘤等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式